Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
研究概览
详细说明
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Hubert Chen, MD
- 电话号码:8587044660
- 邮箱:clinicaltrials@vikingtherapeutics.com
学习地点
-
-
Arizona
-
Tucson、Arizona、美国、85741
- 招聘中
- Viking Clinical Site #2020
-
接触:
- 电话号码:520-333-4515
-
-
California
-
Lake Forest、California、美国、92630
- 招聘中
- Viking Clinical Site #2015
-
接触:
- 电话号码:714-550-9990
-
-
Florida
-
Ocoee、Florida、美国、34761
- 招聘中
- Viking Clinical Site #2059
-
接触:
- 电话号码:407-654-2724
-
-
Georgia
-
Atlanta、Georgia、美国、30329
- 招聘中
- Viking Clinical Site #2013
-
接触:
- 电话号码:404-920-6201
-
-
Indiana
-
Evansville、Indiana、美国、47714
- 招聘中
- Viking Clinical Site #2001
-
接触:
- 电话号码:812-477-2760
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Viking Clinical Site #2046
-
接触:
- 电话号码:504-336-2667
-
Valparaiso、Indiana、美国、46383
- 招聘中
- Viking Clinical Site #2009
-
接触:
- 电话号码:219-464-8302
-
-
Minnesota
-
Richfield、Minnesota、美国、55423
- 招聘中
- Viking Clinical Site #2004
-
接触:
- 电话号码:952-922-7000
-
-
Mississippi
-
Jackson、Mississippi、美国、39206
- 招聘中
- Viking Clinical Site #2029
-
接触:
- 电话号码:770-330-4157
-
-
Missouri
-
Springfield、Missouri、美国、65807
- 招聘中
- Viking Clinical Site #2028
-
接触:
- 电话号码:504-338-0917
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87107
- 招聘中
- Viking Clinical Site #2052
-
接触:
- 电话号码:505-243-1627
-
-
New York
-
Binghamton、New York、美国、13905
- 招聘中
- Viking Clinical Site #2039
-
接触:
- 电话号码:607-800-5777
-
-
Oregon
-
Medford、Oregon、美国、97504
- 招聘中
- Viking Clinical Site #2023
-
接触:
- 电话号码:541-858-1018
-
-
Rhode Island
-
East Greenwich、Rhode Island、美国、02818
- 招聘中
- Viking Clinical Site #2002
-
接触:
- 电话号码:401-739-9350
-
-
South Carolina
-
Charleston、South Carolina、美国、29407
- 招聘中
- Viking Clinical Site #2044
-
接触:
- 电话号码:843-432-2477
-
-
Tennessee
-
Hendersonville、Tennessee、美国、37075
- 招聘中
- Viking Clinical Site #2030
-
接触:
- 电话号码:504-339-0917
-
-
Texas
-
Abilene、Texas、美国、79606
- 招聘中
- Viking Clinical Site #2031
-
接触:
- 电话号码:325-400-1150
-
-
Washington
-
Seattle、Washington、美国、98105
- 招聘中
- Viking Clinical Site #2011
-
接触:
- 电话号码:206-536-3030
-
Spokane、Washington、美国、99218
- 招聘中
- Viking Clinical Site #2042
-
接触:
- 电话号码:509-505-6227
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
实验性的:Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
实验性的:Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
实验性的:Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
大体时间:68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.